Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CRISPR screen for metastasis

The genome-editing technology derived from the bacterial CRISPR/Cas9 system is revolutionizing biomedical research. Using a CRISPR-based strategy, Feng Zhang, Phillip Sharp and colleagues performed a genome-wide loss-of-function genetic screen in vivo, uncovering new genes involved in tumor growth and metastasis (Cell doi:10.1016/j.cell.2015.02.038; 5 March 2015). They started by transducing a non-metastatic lung cancer cell line with a library of 67,405 single-guide RNAs (sgRNAs). When transplanted into immunocompromised mice, the mutated cell pool readily generated metastases in the lung. These tumors were then analyzed to look for gene-specific sgRNA enrichment. The list of top candidates includes known tumor-suppressor genes but also genes with no previously described role in tumor development. This work advances the understanding of cancer evolution and elegantly underscores the potential of CRISPR/Cas9-based screens to study biological phenomena in vivo. It will be interesting to conduct similar cancer studies in other organs, potentially using gain-of-function approaches to identity novel oncogenes.


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Faial, T. CRISPR screen for metastasis. Nat Genet 47, 311 (2015).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing